Assembly Biosciences, Inc.
NASDAQ:ASMBBiotechnology
+$0.16 today
- Market cap
- $458.48M
- Beta
- 1.08
- P/E (TTM)
- -64.4
- EPS (TTM)
- -$0.38
Volume 0.49M
Average 0.17M
ASMB Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Assembly Biosciences, Inc.NASDAQ: ASMB
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q1 FY2026 stock-based compensation of $1.12M rose 56.7% year over year, behind the +64.3% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 23.6% from the prior quarter. Over 3 fiscal years it compounded at -10.8% a year.
Context
- Stock-based compensation amounted to 6.5% of revenue in FY2025, down 4.5 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +56.7% toward the trailing-twelve-month pace of +64.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 4.68M USD
- Year-over-year change
- +49.9%
- 4-year CAGR
- -2.8%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.68M | +49.9% |
| FY2024 | 2024-12-31 | 3.12M | -39.1% |
| FY2023 | 2023-12-31 | 5.12M | -22.4% |
| FY2022 | 2022-12-31 | 6.59M | +25.9% |
| FY2021 | 2021-12-31 | 5.24M | — |
Stock-Based Compensation vs competitors
How ASMB compares with its peers on the latest reported figures
- ASMB's LTM Mar 2026 stock-based compensation of $5.08M is the 5th largest of the 6 companies compared; the peer median is $17.5M.
- Its year-over-year change of +64.3% is the 2nd highest of 6, against a peer median of -32.6%.
- Stock-based compensation amounts to 7.1% of revenue for ASMB, versus a peer median of 22.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $35.01M | +17.1% | -21.7% | 53.5% | |
| LTM Mar 2026 | $18.43M | +74.9% | -1.1% | 9.6% | |
| LTM Mar 2026 | $17.5M | -62.1% | -23.7% | — | |
| LTM Mar 2026 | $15.77M | -32.9% | -11.7% | 22.8% | |
| LTM Mar 2026 | $5.08M | +64.3% | -10.8% | 7.1% | |
| LTM Mar 2026 | $1.19M | -32.6% | -22.8% | — | |
| Peer median (excluding ASMB) | $17.5M | -32.6% | -21.7% | 22.8% | |
Competitors are the stored peer set for ASMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (129.86M) | (93.09M) | (61.23M) | (40.18M) | (6.12M) |
| Depreciation & Amortization | 466K | 498K | 450K | 129K | 129K |
| Deferred Income Tax | (2.53M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.24M | 6.59M | 5.12M | 3.12M | 4.68M |
| Change in Working Capital | (11.4M) | (2.12M) | 76.34M | (11.95M) | (38.28M) |
| Accounts Receivables | 894K | (608K) | 901K | 43K | (974K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.94M) | (166K) | (2.03M) | 124K | 586K |
| Other Working Capital | (10.36M) | (1.35M) | 77.47M | (12.12M) | (37.89M) |
| Other Non-Cash Items | 44.69M | 3.66M | 2.06M | (2.24M) | (1.5M) |
| Operating Cash Flow | (93.4M) | (84.46M) | 22.74M | (51.12M) | (41.09M) |
| Capital Expenditures | (3.1M) | (102K) | (255K) | (28K) | (66K) |
| Acquisitions (Net) | 1.5M | 1.5M | 0 | 0 | 0 |
| Purchases of Investments | (160.45M) | (27.58M) | (133.92M) | (90.5M) | (232.18M) |
| Sales of Investments | 187.7M | 116.83M | 65.02M | 130.7M | 116.43M |
| Other Investing Activities | 857K | 0 | 24K | 0 | 2.35M |
| Investing Cash Flow | 26.52M | 90.64M | (69.14M) | 40.17M | (113.47M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 52.81M | 325K | 13.69M | 29.29M | 174.67M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 258K | 289K | 129K | 155K | 0 |
| Financing Cash Flow | 53.06M | 614K | 13.82M | 29.45M | 174.67M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (13.82M) | 6.79M | (32.58M) | 18.5M | 20.11M |
| Free Cash Flow | (96.49M) | (84.57M) | 22.49M | (51.15M) | (41.16M) |
Assembly Biosciences, Inc.
NASDAQ:ASMB
Intrinsic Alpha fair value
Locked
Current Price
$22.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.